Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells

Clinical Cancer Research

Volumn 22, Issue 9, 2016, Pages 2155-2166

  Schreibelt, Gerty ^a   Bol, Kalijn F ^a,b   Westdorp, Harm ^a,b   Wimmers, Florian ^a   Aarntzen, Erik H J G ^a,b   Duiveman De Boer, Tjitske ^a   Van De Rakt, Mandy W M M ^a   Scharenborg, Nicole M ^a   De Boer, Annemiek J ^a   Pots, Jeanette M ^a   Olde Nordkamp, Michel A M ^a   Van Oorschot, Tom G M ^a   Tel, Jurjen ^a   Winkels, Gregor ^c   Petry, Katja ^c   Blokx, Willeke A M ^b   Van Rossum, Michelle M ^b   Welzen, Marieke E B ^b   Mus, Roel D M ^a   Croockewit, Sandra A J ^b   Koornstra, Rutger H T ^b   Jacobs, Joannes F M ^b   Kelderman, Sander ^d   Blank, Christian U ^d   Gerritsen, Winald R ^b   Punt, Cornelis J A ^e   Figdor, Carl G ^a   De Vries, I Jolanda M ^a,b   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MILTENYI BIOTEC GMBH   (Germany)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD1C ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KEYHOLE LIMPET HEMOCYANIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM SURVIVAL; MALE; METASTATIC MELANOMA; MIDDLE AGED; MYELOID DENDRITIC CELL; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR REGRESSION; VACCINATION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; IMMUNOLOGY; MELANOMA; METASTASIS; MONOCYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL4; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-GAMMA; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84969194975     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2205     Document Type: Article

References (48)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
3. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.
4. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, van Rossum MM, et al. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell based vaccination in metastatic melanoma. Cancer Res 2012;72:6102-10.
5. de Vries IJM, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJP, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.
6. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
7. Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, et al. Dendritic cells differentiated in the presence of IFN-beta and IL-3 are potent inducers of an antigen-specific CD8(+) T cell response. J Leukoc Biol 2005;78:898-908.
8. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J. IL-4 downregulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J Immunol 2003;170: 3306-14.
9. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259-62.
10. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013;31:563-604.
11. Piccioli D, Sammicheli C, Tavarini S, Nuti S, Frigimelica E, Manetti AGO, et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperationwith myeloid dendritic cells for maturation. Blood 2009;113:4232-9.
12. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003;197:101-9.
13. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003;33:1052-62.
14. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, itez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73:1063-75.
15. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001;31:3388-93.
16. Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013;122:932-42.
17. Bakdash G, Schreurs I, Schreibelt G, Tel J. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Rev Clin Immunol 2014;10:915-26.
18. Wilkinson R, Kassianos AJ, Swindle P, Hart DN, Radford KJ. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006;66:180-92.
19. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ. Characterization of human blood dendritic cell subsets. Blood 2002;100: 4512-20.
20. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
21. de Vries IJM, Lesterhuis WJ, Scharenborg NM, Engelen LPH, Ruiter DJ, Gerritsen MJP, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advancedmelanoma patients. Clin Cancer Res 2003;9:5091-100.
22. Aarntzen EH, De Vries IJ, Goertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, et al. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother 2012;61:2003-11.
23. Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, Figdor CG, Jacobs JFM, Tel J, et al. Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. Onco Immunology 2016;5:1:e1067745.
24. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of postcytometric complex multivariate datasets. Cytometry A 2011;79:167-74.
25. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121:95-105.
26. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9.
27. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008;38:350-63.
28. Skold AE, van Beek JJ, Sittig SP, Bakdash G, Tel J, Schreibelt G, et al. Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunol Immunother 2015;64:1461-73.
29. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494: 361-5.
30. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
31. Seder RA, Darrah PA, Roederer M. T-cell quality inmemory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-58.
32. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, De Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012;18:5460-70.
33. Bol K, Aarntzen EHJG, in't Hout FEM, Schreibelt G, Creemers JHA, Lesterhuis WJ, et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Onco Immunology 2016;5:1.
34. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24.
35. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
36. Robert C, Thomas L, Bondarenko I, O'Day S, Jw MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
37. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375-84.
38. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
39. Pierret L, Wilgenhof S, Corthals J, Roelandt T, Thielemans K, Neyns B. Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. J Clin Oncol 27, 2009 (suppl; abstr e20006).
40. Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJ. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocytederived DCs to naturally circulating DC subsets. Front Immunol 2014;5:165
41. Lou YY, Liu CW, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigenspecific antitumor immune responses. J Immunol 2007;178:1534-41.
42. Cantisani R, Sammicheli C, Tavarini S, D'Oro U, Wack A, Piccioli D. Surface molecules on stimulated plasmacytoid dendritic cells are sufficient to cross-activate resting myeloid dendritic cells. Hum Immunol 2011;72: 1018-21.
43. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010;207:1273-81.
44. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247-60.
45. Poulin LF, Salio M, Griessinger E, njos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010;207: 1261-71.
46. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The Ctype lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012;119:2284-92.
47. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013;121:459-67.
48. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013;210:1035-47.